Why is Glenmark Pharmaceuticals Ltd. falling/rising?

Consistent Outperformance Against Benchmarks

Glenmark Pharmaceuticals has demonstrated remarkable resilience and growth compared to broader market indices. Over the past week, the stock surged by 4.10%, significantly outpacing the Sensex’s modest 1.00% gain. This trend extends over longer periods, with the stock delivering a 10.92% return in the last month against the Sensex’s 0.34%, and an impressive 27.21% year-to-date return compared to the benchmark’s 9.45%. The one-year return of 32.04% further underscores Glenmark’s superior performance relative to the Sensex’s 8.89% during the same period. Even more striking is the stock’s three-year return of 377.01%, dwarfing the Sensex’s 42.91% gain, highlighting Glenmark’s sustained growth trajectory and investor appeal.

Technical Strength and Investor Participation

On the trading day of 23-Dec, Glenmark’s stock price touched an intraday high of ₹2,082, marking a 2.13% increase from its previous close. The stock has been on a four-day consecutive gain streak, accumulating a 5.08% return during this period. Importantly, Glenmark is trading above all major moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—signalling robust technical momentum and positive market sentiment. Investor participation has also surged, with delivery volumes on 22-Dec rising by 101.94% to 3.35 lakh shares compared to the five-day average, indicating heightened buying interest and confidence among market participants. The stock’s liquidity remains healthy, supporting sizeable trade volumes without significant price disruption.

Robust Financial Fundamentals Driving Confidence

Underlying Glenmark’s stock appreciation is its exceptional financial performance. The company reported a staggering net profit growth of 1199.62% in its September 2025 results, reflecting operational excellence and effective cost management. Its return on capital employed (ROCE) for the half-year stands at a high 35.65%, while the operating profit to interest ratio for the quarter is an impressive 35.50 times, indicating strong earnings relative to debt servicing costs. Glenmark’s cash and cash equivalents have also reached a peak of ₹2,690.24 crore, providing ample liquidity and financial flexibility.

The company’s return on equity (ROE) of 23.5% and a price-to-book value of 6 suggest an attractive valuation, especially considering the stock trades at a discount relative to its peers’ historical averages. Over the past year, profits have surged by 554.2%, far outstripping the stock’s 32.04% price appreciation, resulting in a very low PEG ratio of 0.1. This indicates that the stock remains undervalued relative to its earnings growth potential, making it an appealing proposition for investors seeking growth at a reasonable price.

Institutional Backing and Consistent Returns

Institutional investors hold a significant 39.38% stake in Glenmark Pharmaceuticals, reflecting strong confidence from knowledgeable market participants. Their holdings have increased by 1.08% over the previous quarter, signalling continued endorsement of the company’s fundamentals and growth prospects. This institutional support often translates into greater stability and reduced volatility for the stock.

Moreover, Glenmark has consistently outperformed the BSE500 index over the last three years, reinforcing its status as a reliable growth stock. The combination of strong returns, solid fundamentals, and technical strength has created a favourable environment for the stock’s recent gains.

Conclusion: A Stock Poised for Continued Strength

Glenmark Pharmaceuticals Ltd.’s recent price rise is firmly rooted in its outstanding financial results, strong operational metrics, and sustained investor interest. The stock’s ability to outperform both its sector and broader market indices, combined with robust technical indicators and rising institutional participation, underscores its appeal as a growth-oriented investment. While the company maintains a conservative debt profile and ample cash reserves, its attractive valuation metrics relative to earnings growth further enhance its investment case. As a result, Glenmark’s stock is well-positioned to maintain its upward trajectory in the near term, supported by both fundamental strength and positive market sentiment.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →